Cetera Investment Advisers Invests $470,000 in Align Technology, Inc. (ALGN) Stock

Cetera Investment Advisers bought a new position in Align Technology, Inc. (NASDAQ:ALGN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,100 shares of the medical equipment provider’s stock, valued at approximately $470,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Oppenheimer & Co. Inc. bought a new stake in Align Technology in the second quarter valued at approximately $1,768,000. AQR Capital Management LLC lifted its position in Align Technology by 36.7% in the first quarter. AQR Capital Management LLC now owns 94,715 shares of the medical equipment provider’s stock valued at $10,865,000 after purchasing an additional 25,422 shares during the last quarter. American Century Companies Inc. lifted its position in Align Technology by 2,236.0% in the second quarter. American Century Companies Inc. now owns 221,009 shares of the medical equipment provider’s stock valued at $33,178,000 after purchasing an additional 211,548 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in Align Technology by 17.8% in the second quarter. Robeco Institutional Asset Management B.V. now owns 90,969 shares of the medical equipment provider’s stock valued at $13,657,000 after purchasing an additional 13,753 shares during the last quarter. Finally, Chevy Chase Trust Holdings Inc. bought a new stake in Align Technology in the second quarter valued at approximately $9,854,000. 81.53% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Align Technology from a “strong-buy” rating to a “hold” rating in a report on Monday, August 21st. Morgan Stanley restated an “overweight” rating and set a $220.00 target price (up previously from $195.00) on shares of Align Technology in a report on Friday, October 6th. Northcoast Research restated a “buy” rating and set a $230.00 target price (up previously from $200.00) on shares of Align Technology in a report on Tuesday, October 10th. Leerink Swann upped their target price on Align Technology from $149.00 to $194.00 and gave the company an “outperform” rating in a report on Monday, June 26th. Finally, Robert W. Baird restated a “buy” rating on shares of Align Technology in a report on Tuesday, September 12th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Align Technology has a consensus rating of “Buy” and a consensus target price of $198.50.

Align Technology, Inc. (NASDAQ:ALGN) traded down 0.27% during midday trading on Thursday, hitting $193.71. The stock had a trading volume of 128,853 shares. Align Technology, Inc. has a 52-week low of $83.27 and a 52-week high of $194.98. The company’s 50 day moving average price is $185.70 and its 200-day moving average price is $156.83. The stock has a market cap of $15.53 billion, a PE ratio of 66.34 and a beta of 1.54.

Align Technology (NASDAQ:ALGN) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.85 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.12. The firm had revenue of $356.50 million during the quarter, compared to analyst estimates of $343.43 million. Align Technology had a return on equity of 23.87% and a net margin of 19.18%. The business’s revenue for the quarter was up 32.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.62 EPS. Analysts forecast that Align Technology, Inc. will post $3.41 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Oppenheimer & Co. Inc. bought a new stake in Align Technology in the second quarter valued at approximately $1,768,000. AQR Capital Management LLC lifted its position in Align Technology by 36.7% in the first quarter. AQR Capital Management LLC now owns 94,715 shares of the medical equipment provider’s stock valued at $10,865,000 after purchasing an additional 25,422 shares during the last quarter. American Century Companies Inc. lifted its position in Align Technology by 2,236.0% in the second quarter. American Century Companies Inc. now owns 221,009 shares of the medical equipment provider’s stock valued at $33,178,000 after purchasing an additional 211,548 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in Align Technology by 17.8% in the second quarter. Robeco Institutional Asset Management B.V. now owns 90,969 shares of the medical equipment provider’s stock valued at $13,657,000 after purchasing an additional 13,753 shares during the last quarter. Finally, Chevy Chase Trust Holdings Inc. bought a new stake in Align Technology in the second quarter valued at approximately $9,854,000. 81.53% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Align Technology from a “strong-buy” rating to a “hold” rating in a report on Monday, August 21st. Morgan Stanley restated an “overweight” rating and set a $220.00 target price (up previously from $195.00) on shares of Align Technology in a report on Friday, October 6th. Northcoast Research restated a “buy” rating and set a $230.00 target price (up previously from $200.00) on shares of Align Technology in a report on Tuesday, October 10th. Leerink Swann upped their target price on Align Technology from $149.00 to $194.00 and gave the company an “outperform” rating in a report on Monday, June 26th. Finally, Robert W. Baird restated a “buy” rating on shares of Align Technology in a report on Tuesday, September 12th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Align Technology has a consensus rating of “Buy” and a consensus target price of $198.50.

Align Technology, Inc. (NASDAQ:ALGN) traded down 0.27% during midday trading on Thursday, hitting $193.71. The stock had a trading volume of 128,853 shares. Align Technology, Inc. has a 52-week low of $83.27 and a 52-week high of $194.98. The company’s 50 day moving average price is $185.70 and its 200-day moving average price is $156.83. The stock has a market cap of $15.53 billion, a PE ratio of 66.34 and a beta of 1.54.

Align Technology (NASDAQ:ALGN) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.85 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.12. The firm had revenue of $356.50 million during the quarter, compared to analyst estimates of $343.43 million. Align Technology had a return on equity of 23.87% and a net margin of 19.18%. The business’s revenue for the quarter was up 32.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.62 EPS. Analysts forecast that Align Technology, Inc. will post $3.41 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://ledgergazette.com/2017/10/19/cetera-investment-advisers-invests-470000-in-align-technology-inc-algn-stock.html.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Want to see what other hedge funds are holding ALGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Align Technology, Inc. (NASDAQ:ALGN).

Institutional Ownership by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply